{
  "doc_type": "other",
  "party_a_name": "Dova Pharmaceuticals, Inc.",
  "party_b_name": "Valeant Pharmaceuticals North America LLC",
  "effective_date": "2018-09-26",
  "term_length": 48,
  "governing_law": null,
  "termination_notice_days": null,
  "liability_cap": "No monetary liability cap stated; excludes consequential/incidental/indirect/special/punitive damages, with carve-outs for indemnification and confidentiality breaches.",
  "non_solicit_clause_present": true,
  "data_transfer_outside_uk_eu": "unknown",
  "risk_level": "medium",
  "risk_explanation": "The agreement contains broad mutual indemnities and no explicit monetary cap on liability, which can create open-ended exposure for a small vendor. It does include a mutual waiver of consequential damages, but that waiver does not limit third-party indemnity obligations or confidentiality-breach damages. Termination-for-convenience notice is redacted, adding uncertainty around exit rights and operational risk.",
  "_meta": {
    "pdf": "C:\\Users\\sohai\\contractFlow\\data\\raw_pdfs\\cuad_008_dovapharmaceuticalsinc_20181108_10_q_ex_.pdf",
    "model": "gpt-5.2",
    "mode": "naive",
    "input_tokens": 39774,
    "output_tokens": 201,
    "validate": true,
    "strict": false,
    "coerce": true,
    "structured_outputs": true,
    "issues": [
      "Field 'governing_law' must not be 'unknown' (reserved for data_transfer_outside_uk_eu)"
    ],
    "retrieval": {
      "enabled": false
    }
  }
}
